Home  
  Our Team  
  Patient Info  
  Services  
   
  Pay My Bill  
  Contact Us  

News for Healthier Living

Assessment of HER2 Status in Extramammary Paget Disease and Its Implication for Disitamab Vedotin, a Novel Humanized Anti-HER2 Antibody-Drug Conjugate Therapy

Researchers from National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Peking University Cancer Hospital & Institute, et al. have conducted a paper entitled "Assessment of HER2 status in extramammary Paget disease and its implication for disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate therapy". This study was published in Frontiers of Medicine, Volume 18, Issue 3.

November 7, 2025


November 7 2025

November 6 2025

November 5 2025

November 4 2025

November 3 2025

November 2 2025

November 1 2025

October 31 2025

October 30 2025

October 29 2025

October 28 2025

October 27 2025

October 26 2025

October 25 2025

October 24 2025